Uroxatral is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Concordia Pharmaceuticals Inc.. The primary component is Alfuzosin Hydrochloride.
| Product ID | 59212-200_2f119319-ba14-4824-a2dd-5e01f737674a | 
| NDC | 59212-200 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Uroxatral | 
| Generic Name | Alfuzosin Hcl | 
| Dosage Form | Tablet, Extended Release | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2013-06-03 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA021287 | 
| Labeler Name | Concordia Pharmaceuticals Inc. | 
| Substance Name | ALFUZOSIN HYDROCHLORIDE | 
| Active Ingredient Strength | 10 mg/1 | 
| Pharm Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2020-12-31 | 
| Marketing Start Date | 2013-06-03 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA021287 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 2013-06-03 | 
| Marketing End Date | 2019-01-31 | 
| Marketing Category | NDA | 
| Application Number | NDA021287 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2013-06-03 | 
| Marketing Category | NDA | 
| Application Number | NDA021287 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 2019-01-18 | 
| Ingredient | Strength | 
|---|---|
| ALFUZOSIN HYDROCHLORIDE | 10 mg/1 | 
| SPL SET ID: | 9fc7f119-f36b-44cf-945d-940160f3afe3 | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  UROXATRAL  76233890  2679884 Live/Registered | Concordia Pharmaceuticals Inc. 2001-03-28 |